DNA Microarray Analysis of Chimpanzee Liver during Acute Resolving Hepatitis C Virus Infection
暂无分享,去创建一个
[1] R. Lanford,et al. Infectious cDNA clone of the hepatitis C virus genotype 1 prototype sequence. , 2001, The Journal of general virology.
[2] C. Rice,et al. Efficient initiation of HCV RNA replication in cell culture. , 2000, Science.
[3] F. Bazzoni,et al. The neutrophil as a cellular source of chemokines , 2000, Immunological reviews.
[4] T. Mizuno,et al. Eradication of hepatitis C virus 1b by interferon in a health care worker with acute hepatitis following needlestick transmission from a patient with chronic hepatitis C unresponsive to interferon. , 2000, Scandinavian journal of gastroenterology.
[5] Samir K. Gupta,et al. A Dose‐Ranging Study of Pegylated Interferon Alfa‐2b and Ribavirin in Chronic Hepatitis C , 2000 .
[6] B. Walker,et al. Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus , 2000, The Journal of experimental medicine.
[7] L. Laimins,et al. Microarray Analysis Identifies Interferon-Inducible Genes and Stat-1 as Major Transcriptional Targets of Human Papillomavirus Type 31 , 2000, Journal of Virology.
[8] Guido Gerken,et al. Local control of the immune response in the liver , 2000, Immunological reviews.
[9] D. Metz,et al. The liver as a site of T‐cell apoptosis: graveyard, or killing field? , 2000, Immunological reviews.
[10] Roger E Bumgarner,et al. Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays. , 2000, Virology.
[11] T. Layden. Principles of interferon induction therapy. , 1999, The American journal of medicine.
[12] Scott A. Rifkin,et al. Microarray analysis of Drosophila development during metamorphosis. , 1999, Science.
[13] H. Kwon,et al. Interferon regulatory factors: the next generation. , 1999, Gene.
[14] F. Chisari,et al. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence , 1999, Hepatology.
[15] H. Bonkovsky,et al. IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[16] C. K. Lee,et al. Gene expression profile of aging and its retardation by caloric restriction. , 1999, Science.
[17] L. Pelicano,et al. Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells , 1999, Leukemia.
[18] D. R. Taylor,et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. , 1999, Science.
[19] M. Caruso,et al. Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. , 1999, Anticancer research.
[20] T. Taniguchi,et al. Activation of the Transcription Factor ISGF3 by Interferon-gamma , 1999, Biological chemistry.
[21] E. Keeffe,et al. Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference , 1999, Journal of gastroenterology and hepatology.
[22] M. Shapiro,et al. Viral clearance without destruction of infected cells during acute HBV infection. , 1999, Science.
[23] P Parham,et al. Analysis of a successful immune response against hepatitis C virus. , 1999, Immunity.
[24] A. Neumann,et al. Hepatitis C Virus Kinetics , 1999, Antiviral therapy.
[25] R. Lanford,et al. Viral Persistence, Antibody to E1 and E2, and Hypervariable Region 1 Sequence Stability in Hepatitis C Virus-Inoculated Chimpanzees , 1999, Journal of Virology.
[26] B. Williams,et al. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays , 1998 .
[27] T. Gingeras,et al. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[28] D. Levy,et al. Differential viral induction of distinct interferon‐α genes by positive feedback through interferon regulatory factor‐7 , 1998, The EMBO journal.
[29] H. Rackwitz,et al. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases , 1998, Cell and Tissue Research.
[30] G. Stark,et al. How cells respond to interferons. , 1998, Annual review of biochemistry.
[31] Michael G. Katze,et al. Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation , 1998, Molecular and Cellular Biology.
[32] J. Trapani,et al. The Human Interferon-inducible Protein, IFI 16, Is a Repressor of Transcription* , 1998, The Journal of Biological Chemistry.
[33] R. Lanford,et al. Analysis of Hepatitis C Virus-Inoculated Chimpanzees Reveals Unexpected Clinical Profiles , 1998, Journal of Virology.
[34] R. Timpl,et al. Mac‐2 binding protein is a cell‐adhesive protein of the extracellular matrix which self‐assembles into ring‐like structures and binds β1 integrins, collagens and fibronectin , 1998, The EMBO journal.
[35] C. Lowenstein,et al. Midkine Induces Tumor Cell Proliferation and Binds to a High Affinity Signaling Receptor Associated with JAK Tyrosine Kinases* , 1998, The Journal of Biological Chemistry.
[36] T. Muramatsu,et al. Midkine, a retinoic acid-inducible heparin-binding cytokine, is a novel regulator of intracellular calcium in human neutrophils. , 1997, Biochemical and biophysical research communications.
[37] W. D. Fairlie,et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Pagano,et al. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency , 1997, Molecular and cellular biology.
[39] J. Darnell. STATs and gene regulation. , 1997, Science.
[40] K Koike,et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. , 1997, The Journal of general virology.
[41] S. Wadler,et al. Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] F. Chisari. Cytotoxic T cells and viral hepatitis. , 1997, The Journal of clinical investigation.
[43] N. Ishimura,et al. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. , 1997, Journal of hepatology.
[44] T. Mak,et al. The transcription factor interferon regulatory factor-1 is essential for natural killer cell function in vivo , 1996, The Journal of experimental medicine.
[45] G. Pape,et al. The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C , 1996, Journal of Molecular Medicine.
[46] N. Tinari,et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. , 1996, Journal of hepatology.
[47] Andrew N. Rowan. Guide for the Care and Use of Laboratory Animals , 1996 .
[48] A. Haas,et al. Immunoregulatory properties of ISG15, an interferon-induced cytokine. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[49] C A Smith,et al. Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.
[50] N. Mechti,et al. Molecular Cloning of a New Interferon-induced Factor That Represses Human Immunodeficiency Virus Type 1 Long Terminal Repeat Expression (*) , 1995, The Journal of Biological Chemistry.
[51] N. Kitamura,et al. Induction of the human gene for p44, a hepatitis-C-associated microtubular aggregate protein, by interferon-alpha/beta. , 1994, European journal of biochemistry.
[52] Matthew J. Brauer,et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.
[53] R. Purcell,et al. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[54] R. Lanford,et al. The chimpanzee model of hepatitis C virus infections. , 2001, ILAR journal.
[55] H J Alter,et al. Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.
[56] P. Glue,et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. , 2000, Hepatology.
[57] C. Biron,et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. , 1999, Annual review of immunology.
[58] J. Silver,et al. Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line , 1999 .
[59] Y. Goltsev,et al. Tumor necrosis factor receptor and Fas signaling mechanisms. , 1999, Annual review of immunology.
[60] W. Leonard,et al. Jaks and STATs: biological implications. , 1998, Annual review of immunology.
[61] B. Williams,et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[62] B Dewald,et al. Human chemokines: an update. , 1997, Annual review of immunology.
[63] Hepatitis C: global prevalence. , 1997, Releve epidemiologique hebdomadaire.